Ratio Therapeutics secures $70m Series C funding for cancer radiotherapy
Ratio Therapeutics, a US-based developer of radiopharmaceuticals for cancer treatment, has closed a $70m Series C financing round.
Read the full article on the original site.
Read Full Article